Updated:
LakePharma
LakePharma is a biologics CDMO based in Belmont, California, blending contract manufacturing with direct equity investment in early-stage biotech clients.
LakePharma
LakePharma is a CDMO headquartered in Belmont, California, with additional facilities in the San Francisco Bay Area. The firm specializes in the development and manufacturing of monoclonal antibodies, recombinant proteins, and other biologics for pharmaceutical and biotechnology clients. While LakePharma's primary revenue model is fee-for-service, public information suggests it has also invested directly in some client programs, taking equity alongside service fees. LakePharma's capabilities span cell line development, upstream and downstream process development, analytical development, and clinical-stage and commercial-scale manufacturing. The firm supports clients from early research through Phase III clinical trials and beyond. Its customer base includes both emerging biotechs and large pharmaceutical companies. The firm has disclosed partnerships with entities such as Sorrento Therapeutics (per SEC filings, 2020) and other undisclosed partners. The firm's scale is measured by its facilities and headcount rather than AUM; it operates multiple sites in the Bay Area with a workforce of several hundred employees. No philanthropic arm or separate investment vehicle has been publicly identified. In its public communications, LakePharma emphasizes its focus on speed-to-clinic and technical expertise in complex biologics. LakePharma's structural differentiator is its hybrid CDMO-plus-investor model. By taking equity stakes in its clients, the firm aligns its financial incentives with client success, a posture rare among pure-play CDMOs. This approach allows LakePharma to capture upside beyond service revenue, though it also introduces potential conflicts of interest in client selection and prioritization. The firm's governance around these investments is not publicly detailed.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Belmont
Corporate office
Belmont, CA, United States
Sector focus
Frequently asked questions
What does LakePharma do for clients?
LakePharma operates as a contract development and manufacturing organization (CDMO) for biologics. It provides services including cell line development, upstream and downstream process development, analytical development, and clinical- and commercial-scale manufacturing of monoclonal antibodies, recombinant proteins, and other biologics.
Does LakePharma only act as a service provider, or does it also invest?
LakePharma's primary revenue source is fee-for-service CDMO work. However, based on public disclosures (including SEC filings), the firm has also taken equity positions in some client companies, effectively functioning as a hybrid operator-investor. This model is uncommon among pure CDMOs.
What stages of drug development does LakePharma support?
LakePharma supports biologics development from early research through Phase III clinical trials and commercial production. Its capabilities cover the full manufacturing pipeline for therapeutic antibodies and recombinant proteins.
Who are LakePharma's typical clients?
LakePharma serves both early-stage biotechnology startups and established pharmaceutical companies. Clients include firms developing monoclonal antibodies and other biologic therapeutics. Specific named clients have included Sorrento Therapeutics (per SEC filings, 2020).
Where does the underlying wealth for LakePharma come from?
LakePharma is a private company, and the ultimate source of its capital is not publicly disclosed. Its operational funding likely comes from private investors or internal cash flow from its CDMO services. The firm has not publicly identified a family office endowment as its primary backer.
How large is LakePharma in terms of infrastructure?
LakePharma operates multiple facilities in the San Francisco Bay Area, including a headquarters in Belmont. It employs several hundred people. The firm has not publicly disclosed manufacturing capacity in liters or square footage, but it markets itself as offering clinical- and commercial-scale production.
Are there any known conflicts in LakePharma's dual service-and-investment model?
LakePharma's hybrid model — earning service fees while holding equity in client companies — introduces potential conflicts. The firm may prioritize clients in which it holds equity, or it may face pressure to recommend development paths that maximize its own equity value. LakePharma has not publicly detailed how it manages these conflicts.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: